What is William Blair's Estimate for ALLO Q1 Earnings?

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Allogene Therapeutics in a research note issued to investors on Friday, March 14th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.29) for the quarter. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

A number of other research analysts have also recently commented on ALLO. Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a research note on Friday. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a report on Friday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $9.40.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock traded down $0.11 during trading on Monday, reaching $1.75. 1,710,970 shares of the company's stock were exchanged, compared to its average volume of 3,043,715. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.74. The firm has a market cap of $365.88 million, a price-to-earnings ratio of -1.12 and a beta of 1.02. The company's 50-day moving average is $1.93 and its two-hundred day moving average is $2.31.

Remove Ads

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ALLO. Curi RMB Capital LLC lifted its stake in Allogene Therapeutics by 47.5% during the third quarter. Curi RMB Capital LLC now owns 149,577 shares of the company's stock worth $419,000 after purchasing an additional 48,202 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Allogene Therapeutics in the 3rd quarter worth about $116,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock valued at $1,361,000 after buying an additional 5,642 shares during the period. BNP Paribas Financial Markets grew its position in shares of Allogene Therapeutics by 541.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company's stock valued at $130,000 after buying an additional 39,145 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Allogene Therapeutics during the third quarter worth about $91,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Insider Transactions at Allogene Therapeutics

In other news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company's stock, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares of the company's stock, valued at approximately $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,710 shares of company stock valued at $92,125. 24.30% of the stock is currently owned by corporate insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).